News

Cook Medical SCAI CIVIC PRESERVE Clincal Studies Vena Cava Filter

Cook Medical is engaged in two clinical studies that will provide additional data on the safety and effectiveness of inferior vena cava (IVC) filters.

InspireMD Inc. has enrolled the first patient into the CARENET (CARotid Embolic protection study using microNET) multi-center European...

Edwards Lifesciences Embol-X Glide Protection System Embolic Device Surgery

The U.S. Food and Drug Administration (FDA) issued a Class I Recall of Edwards Lifesciences LLC’s Embol-X Glide ...

Claret Medical Sentinel Cerebral Protection System CPS TAVR Embolic Protection

Claret Medical Inc. received CE marking for the Sentinel Cerebral Protection System (CPS) for embolic protection during transcatheter aortic valve replacement (TAVR). 

Argon Medical OptionElite retrievable inferior vena cava (IVC) filter guidewire

Argon Medical Devices Inc. received clearance from the U.S. Food and Drug Administration (FDA) to begin marketing the OptionElite retrievable inferior ...

cath lab cardiac pacs radiation dose management pci embolic protection devices

Careful documentation of patient selection and procedure appropriateness are critical — yet underutilized — steps in ensuring high-quality clinical care for percutaneous coronary intervention (PCI...

laa occluders structural heart atrial fibrillation atricure atriclip exclusion

AtriCure Inc., a developer of solutions to treat atrial fibrillation, announced the U.S. Food and Drug Administration’s (FDA’s) approval to begin enrollment in a clinical study of AtriCure’s...

Physicians at the Heart Hospital of Austin, enrolled and successfully treated the first patient in the Roadster study, a global, multicenter ...

CardioLogical Solutions announced that it has been issued two additional patents for its family of aortic embolic protection devices designed to prevent stroke and other ischemic complications....

September 9, 2013 — Keystone Heart, a company in the development of cerebral protection devices for interventional cardiology and cardiac surgery procedures, announced its TriGuard cerebral...

Cerebral function is the essence of quality of life. Its preservation throughout medical procedures is a key component to procedural success and patient care. New scientific data presented at the...

Continuing its commitment to provide best-in-class medical devices for the prevention of recurrent pulmonary embolism (PE), Argon Medical Devices Inc. launched the OptionELITE Retrievable ...

CardioLogical Solutions is an emerging cardiovascular device company formed by the merger of Emboline and VasoStitch and its breakthrough platform of accessory devices for transcatheter aortic...

Angioslide TriVentures Financing Embolic Protection Devices PAD

Angioslide announced the closing of $6.3 million financing led by new investor TriVentures. In addition Biostar joined returning investors Viola Partners, Agate and XT Investments to complete the...

July 13, 2012 — Angioslide Ltd., a provider of embolic capture angioplasty solutions, today announced the successful deployment of a 3x100 mm Proteus device for treating peripheral artery...

June 28, 2012 — BiO2 Medical Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colo., announced...

May 4, 2012 - Angioslide Ltd., a provider of embolic capture angioplasty solutions, announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its new 3x100 mm...

May 4, 2012 - SMT Research & Development Ltd. (SMT) announced the addition of three key executives to its management team, including a new CEO, CFO and chief medical officer, plus two...

Each year I attend Transcatheter Cardiovascular Therapeutics (TCT), I comb the event and its sessions looking for the next big trend or technological innovations in cardiovascular devices. Below...

November 15, 2011 – Results from the PROFI study indicate that the use of a proximal balloon occlusion in carotid artery stenting lead to fewer cerebral ischemic lesions...